Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.66 |
| ▸ | METAP2 | P50579 | 4/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16377373 | 0.85 | ROCK2 (0.64) | ROCK2METAP2PARP1CSNK2A1CSNK2A2 | |
| SCHEMBL16344952 | 0.83 | ROCK2 (0.48) | ROCK2PARP1CSNK2A1PTGER4CSNK2A2 | |
| SCHEMBL16345008 | 0.83 | ROCK2 (0.62) | ROCK2METAP2PARP1CSNK2A1PTGER4 | |
| SCHEMBL18901205 | 0.82 | ROCK2 (0.77) | ROCK2METAP2 | |
| SCHEMBL16345009 | 0.81 | ROCK2 (0.47) | ROCK2PARP1CSNK2A1PTGER4CSNK2A2 | |
| SCHEMBL18901407 | 0.81 | ROCK2 (0.47) | ROCK2PARP1CSNK2A1PTGER4CSNK2A2 | |
| SCHEMBL17783685 | 0.80 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL17783683 | 0.80 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL18901231 | 0.79 | ROCK2 (0.45) | ROCK2PARP1CSNK2A1PTGER4CSNK2A2 | |
| SCHEMBL16345968 | 0.79 | ROCK2 (0.62) | ROCK2METAP2PARP1CSNK2A1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3016951-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015002915-A1 | TRICYCLIC PYRI DO-CARBOXAM I D E DERIVATIVES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015002915-A1 | TRICYCLIC PYRI DO-CARBOXAM I D E DERIVATIVES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | ROCK2 4/4885METAP2 3409/4885PARP1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.